Adalvo and Eurolab are pleased to announce the extension of their long-term strategic collaboration, signing a basket deal for three more products to be marketed and distributed in South Africa and as well as certain SSA countries. The current global market size of the products included in this deal exceeded US$2BN in 2022, according to IQVIA.
These value-added products encompass a diverse range of segments, each catering to specific indications and fulfilling unique patient needs. The portfolio offers a broad list of therapeutic products, some of which include specialty medicine for Pain Relief, Leukaemia, and an exclusive collaboration for Benign Prostatic Hyperplasia (BPH).
With this solid partnership, Eurolab and Adalvo continue to strengthen their position in South Africa and SSA regions, providing patients with high-quality and affordable treatment options.
Anil Okay, CEO of Adalvo, expressed his enthusiasm, saying, "We are proud to continue our partnership with Eurolab, a company that shares our dedication to advancing healthcare solutions. Together, we are poised to make a significant impact in South Africa and SSA regions by providing patients with access to innovative and high-quality treatments."
Lynne du Toit, CEO of Eurolab, echoed this sentiment, stating, "The extension of our collaboration with Adalvo represents a milestone in our journey to improve healthcare across South Africa and SSA countries. By combining our strengths and resources, we aim to meet the diverse healthcare needs of these regions while ensuring affordability and accessibility for all."
Adalvo and Eurolab remain committed to their mission of enhancing healthcare standards and look forward to delivering these value-added products to patients in South Africa and SSA countries.
About Adalvo
Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 100 countries and for over 110 commercial partners globally. The company’s declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering highest quality differentiated products and services to our partners.
With headquarters in Malta, the company has additional offices in more than 16 countries. At Adalvo, we know that our partners like to be bigger, better, and smarter in the dynamic pharmaceutical sector. That’s why our approach is unique, customized to our partners, and is designed to challenge the status quo: together, this helps our partners achieve their business goals.
We take pride in our ability to help partners reach their goals – be those increasing revenues or pushing into new markets. While partners are a high priority, Adalvo is also committed to its purpose and mission to accelerate the growth and development of employees and local communities.
The company’s purpose driven culture is committed to improving the lives of patients around the world. Our dynamic leadership team brings significant experience and industry know-how to Adalvo, which has helped to establish the company as a reliable global partner.
About Eurolab
Eurolab is the largest and leading oncology company in South Africa with a focus on generics and biosimilars. Our experienced and award-wining leadership team brings a unique and dynamic edge to Eurolab, allowing us to have established ourselves as a trusted partner in the South African pharmaceutical landscape. We have a full in-house industry leading regulatory and pharmacovigilance team who bring an additional layer of expertise, knowledge, and help expedite the regulatory approval process by efficiently navigating the regulatory pathways and requirements.
Since 2011, Eurolab marked a significant step towards diminishing the financial burdens associated with cancer care in South Africa. Our unwavering commitment to ensuring access to high quality medicines is what distinguishes us, ultimately making cancer treatment a more attainable reality for a wider segment of the population.
With Eurolab’s comprehensive approach, we have expanded and integrated innovative technology and medicines into South Africa’s cancer care environment. We have created access to diverse options for cancer treatment and recovery with our broad portfolio of oncology and haematology products.
This partnership and collaboration has enabled us to introduce affordable high quality treatments into South Africa’s cancer care environment. We will continue to solidify our position as a trusted partner within South Africa’s pharmaceutical landscape